C2I Alumna, RootPath, announces $11M Series A funding to accelerate clinical translation of their Pr

Congratulations to our alumna, RootPath, on raising $11 Million Series A funding to accelerate clinical translation of their personalized, highly-potent T cell therapy powered by their proprietary Synthetic Immunology Platform™! Rootpath will use the Series A funding to validate their tumor-reactive T cell receptor (TCR) discovery workflow, select a lead therapeutic candidate, and demonstrate its safety and efficacy in a preclinical setting and begin IND-enabling development. To read more, view the official press release. Visit Rootpath's website by clicking here. Book a virtual tour online by clicking here.

Featured Posts
Recent Posts
Archive
Search By Tags

© 2019 by CreaGen Inc. 

299 Washington St

Woburn, MA 01801 

Tel: 781.938.1122

Fax: 781.938.1123

 

info@creagenbio.com

  • Grey LinkedIn Icon
  • Grey Twitter Icon
  • Grey YouTube Icon
  • Grey Facebook Icon

Business Accelerator | CreaGen C2I | Life Science | Lease Lab Space | Biotech